Human pain biomarkers are based on standardized acute activation of pain pathways/mechanisms and quantitative assessment of the evoked responses. This approach can be applied to healthy volunteers, to pain patients, and before and after pharmacological interventions to help understanding and profile the mode of action (proof-of-concept) of new and existing analgesic compounds.
Standardized stimuli of different modalities can be applied to different tissues (multimodal and multi-tissue) for profiling analgesic compounds with respect to modulation of pain transduction, transmission, specific mechanisms and processing. This approach substantiates which specific compounds may work in particular clinical pain conditions. Human pain biomarkers can be translational and may bridge animal findings in clinical pain conditions, which in turn can provide new possibilities for designing more successful clinical trials. Biomarker based proof-of-concept drug studies in either volunteers or selected patient populations provide inexpensive, fast and reliable mechanism-based information about dose-efficacy relationships. This is important information in the early drug development phase and for designing large expensive clinical trials.
Read the full article at Pubmed
Working with CCBR speeds up and drives efficiencies in clinical trials by offering greater numbers of patients across fewer sites
A Global Footprint covering more than 20 dedicated Clinical Research Centers in high density population areas
Uniform SOPs enable the tightest possible adherence to study protocols and consistency across all CCBR sites
Real-Time tacking of subject enrolment and trial progress ensures sponsors have the most up to date information, all of the time
Centralised, standardised billing affords better visibility into trial costs for sponsors
